Bicara Therapeutics Inc. Common Stock (BCAX) Stock Price, Quote & AI Analysis

Live BCAX stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Bicara Therapeutics Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Bicara Therapeutics Inc. Common Stock (BCAX), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.

BCAX
Bicara Therapeutics Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
23.640000
High
24.350000
Low
22.820000
Volume
518,793
VWAP
-
Market Cap
$1,549,770,114.28
52W Range
$10.30 - $30.99
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Nov 9, 2026 Q3
Market
EPS Estimate: $-0.8703
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Bicara Therapeutics Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Bicara Therapeutics Inc. Common Stock Overview

Company information

Company Overview

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Company Details
Market Cap
$1.56B
Shares Outstanding
66,172,936
Weighted Shares Outstanding
66,172,934
CEO
Claire Mazumdar
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
Employees
103
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and indicators

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Bicara Therapeutics Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...